Simon Harford compensation by year
AMICUS THERAPEUTICS Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2024 |
|---|---|---|
| Salary | $173,077 | $514,423 |
| Bonus | $111,045 | $275,319 |
| Stock awards | $1,349,999 | $1,862,083 |
| Option awards | $1,346,048 | $785,678 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $416 | $11,562 |
| Total | $2,980,585 | $3,449,065 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AMICUS THERAPEUTICS, INC. DEF 14A filed April 24, 2025, accession 0001140361-25-015479, and prior-year filings. Open the filing on EDGAR.
How this page was built: the AMICUS THERAPEUTICS, INC. filed document, accession 0001140361-25-015479. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 80,230 | $755,767 | — |
| RSU | 57,392 | $540,633 | — |
| PSU | 28,696 | $270,316 | — |
| PSU | 17,217 | $162,184 | — |
| PSU | 11,479 | $108,132 | — |
| Option | 99,073 | — | $14.24 |
| Option | 126,031 | — | $12.62 |
Per the Outstanding Equity Awards at Fiscal Year-End table in AMICUS THERAPEUTICS, INC.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments AMICUS THERAPEUTICS discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $515,000 | $387,077 | $59,251 | $1,193,078 |
| Change in control, no termination | — | $1,296,399 | — | $1,296,399 |
| Change in control and involuntary termination | $772,500 | $1,837,032 | $88,877 | $2,930,159 |
| Death | — | $1,314,792 | $39,501 | $1,354,293 |
| Disability | — | $1,314,792 | $39,501 | $1,354,293 |
Per the Potential Payments Upon Termination or Change in Control table in AMICUS THERAPEUTICS, INC.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
AMICUS THERAPEUTICS’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Bradley Campbell | President and Chief Executive Officer | $8,526,943 |
| Ellen Rosenberg | Chief Legal Officer and Corporate Secretary | $3,800,307 |
| Simon Harford · this page | Chief Financial Officer | $3,449,065 |
| Jeffrey Castelli | Chief Development Officer | $3,442,896 |
| David Clark | Chief People Officer | $3,015,209 |
The full AMICUS THERAPEUTICS compensation record
free company briefThis page is one person within AMICUS THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the AMICUS THERAPEUTICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order AMICUS THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AMICUS THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order FOLD
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.